GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 347
- Registration Number
- NCT01691859
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
RELOVAIR® Lung Deflation Study
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT01691885
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study in Adolescent Females to Explore Cytomegalovirus Infection
- Conditions
- Infections, Cytomegalovirus
- Interventions
- Procedure: Blood collectionProcedure: Urine collectionProcedure: Saliva collection
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 369
- Registration Number
- NCT01691820
- Locations
- 🇲🇽
GSK Investigational Site, Jojutla, Morelos, Mexico
Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
- Conditions
- Dentine Hypersensitivity
- Interventions
- Drug: Sodium monofluorophosphate dentifriceDrug: Sodium fluoride dentifrice
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT01691560
- Locations
- 🇺🇸
BioSci Research America, Las Vegas, Nevada, United States
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT01691508
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
ARIXTRA® Adherence in SVT Patients.
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01691495
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 580
- Registration Number
- NCT01691521
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Albuterol/salbutamol
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01691482
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: UMEC /VIDrug: VIDrug: UMECDrug: FF
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT01691547
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: GSK2586184 single dose taken without foodDrug: GSK2586184 800mg single and repeat doseDrug: Placebo-to-match GSK2586184Other: GSK2586184 single dose taken with food
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT01687309
- Locations
- 🇧🇪
GSK Investigational Site, Antwerpen, Belgium